No Data
Telix Pharmaceuticals Completes Enrollment in Brain Cancer Drug Trial
Telix Completes Enrolment in Phase 1 Glioblastoma Trial
Telix Pharmaceuticals' IPAX-2 Study Of TLX101-Tx Completes Patient Enrolment; Maximum Dose Reached With No Dose-limiting Toxicities Observed; TLX101-Tx Is Also The Subject Of A Pivotal Trial, IPAX BrIGHT, Which Is Actively Dosing Patients With...
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
Global Radiopharmaceuticals Market Set for Significant Expansion at a CAGR of ~10% by 2034 With Increasing Adoption of Targeted Radiotherapy | DelveInsight
Why Is Regeneron Stock Sinking Monday?